People on Ozempic and other GLP-1 agonist drugs commonly report they no longer have constant, incessant thoughts about food. This is how the drugs work.

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion ...

The following is a summary of “Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit ...

Roche is stepping into the hot weight-loss drug market currently dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). The ...